Tysabri Re-Launch Approved With MRI Requirement
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA clears Biogen Idec’s multiple sclerosis therapy to return to market under a special distribution program.
You may also be interested in...
Biogen Idec/Elan Plan To Appeal Negative CHMP Opinion Of Tysabri For Crohn’s
Committee also issues positive opinions on Novartis’ type 2 diabetes therapy Galvus, Pfizer’s oral HIV treatment Celsentri and GSK’s cervical cancer vaccine Cervarix.
Biogen Idec/Elan Plan To Appeal Negative CHMP Opinion Of Tysabri For Crohn’s
Committee also issues positive opinions on Novartis’ type 2 diabetes therapy Galvus, Pfizer’s oral HIV treatment Celsentri and GSK’s cervical cancer vaccine Cervarix.
Biogen Idec/Elan Submit Tysabri sBLA For Crohn’s Disease
Submission includes labeling and risk management plan to address increased risk of progressive multifocal leukoencephalopathy.